37051-23-3

Basic information

• Product Name: (S)-6-(benzyloxy)-2-(tert-butoxycarbonylaMino)-6-oxohexanoic acid
• Synonyms: (S)-6-(benzyloxy)-2-(tert-butoxycarbonylaMino)-6-oxohexanoic acid;N-Boc-R-2-Aminoadipic acid 6-(phenylmethyl) ester
• CAS NO: 37051-23-3
• Molecular Formula: C₁₈H₂₅NO₆
• Molecular Weight: 351.3942
• Mol File: 37051-23-3.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (S)-6-(benzyloxy)-2-(tert-butoxycarbonylaMino)-6-oxohexanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-6-(benzyloxy)-2-(tert-butoxycarbonylaMino)-6-oxohexanoic acid(37051-23-3)
• EPA Substance Registry System: (S)-6-(benzyloxy)-2-(tert-butoxycarbonylaMino)-6-oxohexanoic acid(37051-23-3)

Safety Data

• Hazardous Substances Data: 37051-23-3(Hazardous Substances Data)

Usage

General Description

(S)-6-(Benzyloxy)-2-(tert-butoxycarbonylamino)-6-oxohexanoic acid is a compound with a complex structure, consisting of a six-carbon chain with a carboxylic acid and a ketone group at either end. Additionally, it contains a benzyl ether and a tert-butoxycarbonylamino group, which are commonly used as protecting groups in organic synthesis to prevent undesired reactions. (S)-6-(Benzyloxy)-2-(tert-butoxycarbonylamino)-6-oxohexanoic acid may have potential applications in organic chemistry as a building block for the synthesis of more complex molecules, or as a reagent for specific reactions. Its precise properties and uses would depend on the specific context and goals of the chemical synthesis being carried out.

Upstream product

• 100-51-6 benzyl alcohol 
• 7620-28-2 D-2-aminoadipic acid 
• 110545-02-3 N^α,N^ca-di-tert-butyloxycarbonyl-D-homoglutamine 
• 20194-18-7 sodium phenyl-methanolate 
• 1070-19-5 N-(tert-butyloxycarbonyl) azide 
• 37051-22-2 (R)-2-Amino-hexanedioic acid 6-benzyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 38658-15-0 (S)-2-amino-6-(benzyloxy)-6-oxohexanoic acid 
• 108312-38-5 N^α,N^ε-di-tert-butyloxycarbonyl-L-lysine 2,2,2-trichloroethyl ester 
• 108312-35-2 N^α,N^ca-di-tert-butyloxycarbonyl-L-homoglutamine 
• 58632-95-4 2-(tert-Butoxycarbonyloxyimino)-2-phenylacetonitrile 
• 1118-90-7 L-homoglutamic acid 

Downstream Products

• 171270-54-5 (3S)-3-[(2S)-5-benzyloxycarbonyl-2-(tertiarybutoxycarbonylamino)-pentanoyl]oxyhexadecanamide 
• 124184-51-6 C₂₂H₂₈N₂O₈ 
• 41849-38-1 7α-methoxycephalosporin C 
• 37126-77-5 (6R)-3-acetoxymethyl-7t-[(R)-5-tert-butoxycarbonylamino-5-(2,2,2-trichloro-ethoxycarbonyl)-pentanoylamino]-7c-methoxy-8-oxo-(6rH)-5-thia-1-aza-bicyclo[4.2.0]oct-3-ene-2ξ-carboxylic acid benzhydryl ester 
• 77302-98-8 (S)-2-[(S)-5-Benzyloxycarbonyl-2-((S)-5-benzyloxycarbonyl-2-tert-butoxycarbonylamino-pentanoylamino)-pentanoylamino]-4-methyl-pentanoic acid methyl ester 
• 37051-24-4 (R)-2-tert-Butoxycarbonylamino-hexanedioic acid 6-benzyl ester 1-(2,2,2-trichloro-ethyl) ester 

Relevant articles and documents

CASPASE INHIBITORS AND METHODS OF USE THEREOF

Provided herein are compounds of formula (I), compositions comprising the compounds and method of treating various diseases with the compounds and compositions.

Synthesis and biological evaluation of boron peptide analogues of Belactosin C as proteasome inhibitors

A series of boron peptides 11, 13, 15 and 17 were designed and synthesized as proteasome inhibitors based on the structure of Belactosin C. Matteson homologation was a key step in the synthesis of the boron peptides. Compounds 11a and 13 showed significant inhibition of 20S proteasome chymotrypsin-like (β5) activity (IC50 = 0.28 and 0.51 μM, respectively). Furthermore, like PS-341, compound 11a increased the G2/M cell distribution. A biparametric cytofluorimetric analysis with FITC-labeled annexin V and propidium iodide showed induction of apoptosis by compound 11a at >1 μM concentrations of compound.

Synthesis of Peptide Analogues of Prothrombin Precursor Sequence 5-9. Substrate Specificity of Vitamin K Dependent Carboxylase

Thirty-five analogues of Phe-Leu-Glu-Glu-Leu, the pentapeptide sequence 5-9 of bovine prothrombin precursor, were synthesized and assayed as potential substrates or inhibitors of rat liver vitamin K dependent carboxylase.Carboxylation of substrate was determined by measuring the incorporation of carbon-14 labeled bicarbonate into product.Changes in substrate carboxylation produced by changing peptide chain length, amino acid chirality, or the distance seperating the peptide chain backbone from the carboxyl group were measured.The data suggest that the carboxylase carboxylates L-glutamic acid residues and does not carboxylate L-aspartic acid, L-homoglutamic acid, glutamine, or D-glutamic acid residues; tri- through pentapeptides are better substrates than mono- or bis(amino acid) derivatives, and hydrophobic groups added to the N-terminus can produce better substrates for the enzyme.None of the synthetic substrates is carboxylated as effectively as the endogenous protein substrates for the enzyme.The effect of structure on additional parameters affecting carboxylation is discussed.